Maxim weighs in on Cytori Therapeutics' (CYTX +18%) new government contract, calling it a...


Maxim weighs in on Cytori Therapeutics' (CYTX +18%) new government contract, calling it a significant strategic positive. The firm reiterates its Buy rating on the stock with a $10 price target.

Comments (1)
  • Jay Murphy
    , contributor
    Comments (51) | Send Message
     
    I like CYTX, but I would like to know their plans for cash flow. This seems to be a good time for them to offer more equity. I'd prefer to buy after the dilution rather than before.
    1 Oct 2012, 04:18 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs